Patents by Inventor Eric Williams Mayoux

Eric Williams Mayoux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20260000696
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: September 4, 2025
    Publication date: January 1, 2026
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20250345352
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: July 21, 2025
    Publication date: November 13, 2025
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 12427162
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 21, 2023
    Date of Patent: September 30, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins
  • Methods for treating and pharmaceutical compositions
    Patent number: 12427161
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sodium glucose co-transporter 2 (SGLT2) inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of phosphodiesterase 5 (PDE5) inhibitors or alprostadil.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: September 30, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Eric Williams Mayoux, Delphine Behr-Roussel, Francois Giuliano
  • METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
    Publication number: 20240277729
    Abstract: The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.
    Type: Application
    Filed: March 6, 2024
    Publication date: August 22, 2024
    Inventors: Marion WIENRICH, Eric Williams MAYOUX
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20240156848
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: January 25, 2024
    Publication date: May 16, 2024
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20240091245
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 21, 2024
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • METHODS FOR TREATING AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240082284
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sodium glucose co-transporter 2 (SGLT2) inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of phosphodiesterase 5 (PDE5) inhibitors or alprostadil.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 14, 2024
    Inventors: Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
  • METHODS OF TREATING DISEASES
    Publication number: 20240082283
    Abstract: The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 14, 2024
    Inventor: Eric Williams MAYOUX
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11918596
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: March 5, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11813275
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11666590
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins
  • METHODS OF TREATING DISEASES
    Publication number: 20220323473
    Abstract: The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 13, 2022
    Inventor: Eric Williams MAYOUX
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220226360
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 21, 2022
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • Methods for treating and Pharmaceutical compositions
    Publication number: 20220193101
    Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.
    Type: Application
    Filed: October 5, 2021
    Publication date: June 23, 2022
    Inventors: Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220110961
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: July 21, 2021
    Publication date: April 14, 2022
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210346418
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: July 21, 2021
    Publication date: November 11, 2021
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z. I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210228610
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: November 10, 2020
    Publication date: July 29, 2021
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF
    Publication number: 20210212968
    Abstract: The invention relates to a pharmaceutical combination according to the invention comprising an SSAO/VAP-1 inhibitor according to the formula (I) wherein R1 to R6, and X are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient.
    Type: Application
    Filed: October 16, 2017
    Publication date: July 15, 2021
    Inventors: Joerg RIPPMANN, Thomas KLEIN, Michael MARK, Eric Williams MAYOUX
  • METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
    Publication number: 20210205324
    Abstract: The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.
    Type: Application
    Filed: October 19, 2020
    Publication date: July 8, 2021
    Inventors: Marion WIENRICH, Eric Williams MAYOUX